Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Short-term Investments (2016 - 2025)

Lipocine's Short-term Investments history spans 10 years, with the latest figure at $11.2 million for Q3 2025.

  • For Q3 2025, Short-term Investments fell 30.16% year-over-year to $11.2 million; the TTM value through Sep 2025 reached $11.2 million, down 30.16%, while the annual FY2024 figure was $15.4 million, 10.64% down from the prior year.
  • Short-term Investments reached $11.2 million in Q3 2025 per LPCN's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $41.7 million in Q4 2021 to a low of $11.2 million in Q3 2025.
  • Average Short-term Investments over 5 years is $24.3 million, with a median of $21.6 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: surged 9159.59% in 2021, then tumbled 41.24% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $41.7 million in 2021, then fell by 29.49% to $29.4 million in 2022, then crashed by 41.24% to $17.3 million in 2023, then fell by 10.64% to $15.4 million in 2024, then decreased by 27.21% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Short-term Investments are $11.2 million (Q3 2025), $11.9 million (Q2 2025), and $16.4 million (Q1 2025).